Simulations Plus Balance Sheet Health

Financial Health criteria checks 6/6

Simulations Plus has a total shareholder equity of $182.4M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $196.6M and $14.2M respectively. Simulations Plus's EBIT is $8.7M making its interest coverage ratio -2. It has cash and short-term investments of $20.3M.

Key information

Debt to equity ratio

US$0

Debt

Interest coverage ratio	-2x
Cash	US$20.26m
Equity	US$182.43m
Total liabilities	US$14.21m
Total assets	US$196.64m

Recent financial health updates

No updates

Recent updates

Simulations Plus: Questionable Whether It Will Benefit Or Be Hurt By Generative AI

Feb 01

We Like Simulations Plus' (NASDAQ:SLP) Earnings For More Than Just Statutory Profit

Jan 12

Capital Allocation Trends At Simulations Plus (NASDAQ:SLP) Aren't Ideal

Nov 06

Estimating The Intrinsic Value Of Simulations Plus, Inc. (NASDAQ:SLP)

Sep 06

Here's What's Concerning About Simulations Plus' (NASDAQ:SLP) Returns On Capital

Jun 28

Some Investors May Be Worried About Simulations Plus' (NASDAQ:SLP) Returns On Capital

Feb 10

With EPS Growth And More, Simulations Plus (NASDAQ:SLP) Makes An Interesting Case

Nov 23

A Look At The Intrinsic Value Of Simulations Plus, Inc. (NASDAQ:SLP)

Oct 21

Here's What's Concerning About Simulations Plus' (NASDAQ:SLP) Returns On Capital

Sep 19

Financial Position Analysis

Short Term Liabilities: SLP's short term assets ($39.3M) exceed its short term liabilities ($12.1M).

Long Term Liabilities: SLP's short term assets ($39.3M) exceed its long term liabilities ($2.1M).

Debt to Equity History and Analysis

Debt Level: SLP is debt free.

Reducing Debt: SLP has not had any debt for past 5 years.

Debt Coverage: SLP has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: SLP has no debt, therefore coverage of interest payments is not a concern.

Simulations Plus Balance Sheet Health

Financial Health criteria checks 6/6

Key information

Recent financial health updates

Recent updates

Simulations Plus, Inc. and University of Connecticut Receive New FDA Grant to Expand Mechanistic Modeling Approaches for Long-Acting Injectables

We Think Simulations Plus' (NASDAQ:SLP) Healthy Earnings Might Be Conservative

Investor sentiment deteriorates as stock falls 16%

Price target decreased by 7.5% to US$52.75

Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Simulations Plus, Inc. Provides Earnings Guidance for Fiscal Year 2025

Simulations Plus, Inc. to Report Q4, 2024 Results on Oct 23, 2024

Simulations Plus and the University of Southern California Secure NIH Grant to Develop New AI Drug Discovery Offerings

Simulations Plus, Inc. Announces Executive Changes, Effective August 30, 2024

Simulations Plus: Declining Margins Are A Problem

Now 21% undervalued after recent price drop

Simulations Plus, Inc. Releases the latest version of its quantitative systems toxicology (QST) platform, DILIsym version X

Upcoming dividend of US$0.06 per share

Simulations Plus: Steady Growth, But What About The Margins?

Consensus EPS estimates fall by 14%

Third quarter dividend of US$0.06 announced

Third quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

Simulations Plus, Inc. Updates Earnings Guidance for the Fiscal 2024

Now 12% overvalued after recent price rise

Now 21% overvalued after recent price rise

Simulations Plus, Inc. to Report Q3, 2024 Results on Jul 02, 2024

Consensus EPS estimates fall by 17%, revenue upgraded

Price target increased by 12% to US$60.33

Simulations Plus, Inc. (NasdaqGS:SLP) acquired Pro-ficiency, LLC from NovaQuest Capital Management, L.L.C., QHP Capital, L.P. and Pro-ficiency’s minority shareholders for approximately $100 million.

Simulations Plus Releases GastroPlus® X, The Next Generation PBPK/PBBM Modeling & Simulation Software

Simulations Plus: Reliance On Consulting And Acquisitions Creates Doubts

lead Independent Director notifies of intention to sell stock

Upcoming dividend of US$0.06 per share

Second quarter dividend of US$0.06 announced

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Now 43% overvalued after recent price rise

Simulations Plus, Inc. Declares a Cash Dividend, Payable on May 6, 2024

Why We're Not Concerned About Simulations Plus, Inc.'s (NASDAQ:SLP) Share Price

Simulations Plus, Inc. to Report Q2, 2024 Results on Apr 03, 2024

Capital Allocation Trends At Simulations Plus (NASDAQ:SLP) Aren't Ideal

Now 22% overvalued after recent price rise

Simulations Plus: Questionable Whether It Will Benefit Or Be Hurt By Generative AI

Simulations Plus, Inc. Releases GastroPlus Version 9.9

Upcoming dividend of US$0.06 per share at 0.6% yield

We Like Simulations Plus' (NASDAQ:SLP) Earnings For More Than Just Statutory Profit

First quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

President of PBPK notifies of intention to sell stock

Simulations Plus, Inc., Annual General Meeting, Feb 08, 2024

Simulations Plus, Inc. to Report Q1, 2024 Results on Jan 03, 2024

Simulations Plus, Inc. Reiterates Earnings Guidance for the Fiscal Year 2024

Capital Allocation Trends At Simulations Plus (NASDAQ:SLP) Aren't Ideal

Price target decreased by 9.1% to US$53.33

Simulations Plus, Inc. Declares Cash Dividend , Payable on November 6, 2023

Simulations Plus, Inc. to Report Q4, 2023 Results on Oct 25, 2023

Simulations Plus Receives New FDA Grant Award

Estimating The Intrinsic Value Of Simulations Plus, Inc. (NASDAQ:SLP)

Upcoming dividend of US$0.06 per share at 0.5% yield

Simulations Plus, Inc. Releases ADMET Predictor® 11

Third quarter 2023 earnings: Revenues and EPS in line with analyst expectations

Simulations Plus, Inc. Declares Cash Dividend , Payable on August 7, 2023

Co-Founder & Chairman notifies of intention to sell stock

Here's What's Concerning About Simulations Plus' (NASDAQ:SLP) Returns On Capital

Simulations Plus, Inc. to Report Q3, 2023 Results on Jul 06, 2023

Simulations Plus, Inc. (NasdaqGS:SLP) acquired Immunetrics, Inc. from LaunchCyte LLC for $23.5 million.

Price target decreased by 12% to US$55.00

Upcoming dividend of US$0.06 per share at 0.5% yield

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

President exercised options to buy US$1.5m worth of stock.

President notifies of intention to sell stock

Simulations Plus Releases Redesigned NAFLDsym QSP Software Tool

Some Investors May Be Worried About Simulations Plus' (NASDAQ:SLP) Returns On Capital

Upcoming dividend of US$0.06 per share

Simulations Plus Releases DILIsym X (DSX) Beta with Redesigned Software Infrastructure

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Simulations Plus, Inc. (NasdaqGS:SLP) announces an Equity Buyback for $50 million worth of its shares.

Co-Founder & Chairman notifies of intention to sell stock

Simulations Plus, Inc., Annual General Meeting, Feb 09, 2023

Price target decreased to US$59.75

Simulations Plus, Inc. to Report Q1, 2023 Results on Jan 04, 2023

With EPS Growth And More, Simulations Plus (NASDAQ:SLP) Makes An Interesting Case